SavedAdd your journal

Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2004 / Cilt: 44 - Sayı: 4

Relationship between myeloid antigen expression and prognosis in the adult acute lymphoblastic leukemia

Erişkin akut lenfoblastik lösemili hastalarda miyeloid antijen sunumu ile prognoz arasındaki ilişki

Nalan USALAN
Atalay SURARDAMAR
Selçuk GÜNDOĞAR
Nurcan HATIRNAZ
Figen NOYAN
Refik DEMİRTUNÇ
Pages
200–204
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is no difference between of remission the time of be-gining therapy, disease free survival, over all survival and recurrence rate in myeloid antigen positive and myeloid antigen negative cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We studied the correlation between prognosis and presence of myeloid antigen found by immunophe-notyping in acute lymphoblastic leukemia (ALL) patients.
📊
Key Findings & Data:Newly diagnosed 55 ALL cases were used in our study which admitted to the Haydarpaşa Numune Hospital between January 1996 and April 2002.
💡
Conclusion & Impact:There is no difference between of remission the time of be-gining therapy, disease free survival, over all survival and recurrence rate in myeloid antigen positive and myeloid antigen negative cases.
🔬Design:Research Article
📍Scope:2002 Verileri
⚙️Variables:Domain Parameters

Abstract

We studied the correlation between prognosis and presence of myeloid antigen found by immunophe-notyping in acute lymphoblastic leukemia (ALL) patients. Newly diagnosed 55 ALL cases were used in our study which admitted to the Haydarpaşa Numune Hospital between January 1996 and April 2002. Twelve TALL (% 21.8), 4 pre T ALL (%7.3), 21 early pre B ALL ( %38.2), 15 pre B ALL (%27.2), 3 B ALL (%5.5) were found by immunophenotyping using flow-cyto-metry method. When we evaluated the expression of myeloid antigen we found in 34.5 percent of our cases that at least one of CD13 and CD33 myeloid antigen was found. Remission rate in cases which expressed one of myeloid antigens were significanly low. There is no difference between of remission the time of be-gining therapy, disease free survival, over all survival and recurrence rate in myeloid antigen positive and myeloid antigen negative cases.

Özet

Çalışmamızda akut lenfoblastik lösemi (ALL) tanısı alan hastalarda immünfenotipleme ile saptanan miyeloid antijen varlığı ile prognoz arasındaki ilişkiyi araştırdık. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Dahiliye Kliniği'ne Ocak 1996 ile Nisan 2002 tarihleri arasında başvuran, yeni tanı konmuş toplam 55 ALL'Iİ olgu çalışmaya alındı. Akım sitometri tekniği ile yapılan immünfenotipik incelemede 12 T ALL (%21.8), 4 pre T ALL (%7.3), 21 erken pre B ALL (%38.2), 15 pre B ALL (%27.2), 3 B ALL (%5.5) saptandı. Miyeloid antijen sunumu açısından değerlendirme yapıldığında olgularımızın %34.5'i CD13 ve CD33 miyeloid antijenlerinden en az birini taşımaktaydı. Re-misyon oranı miyeloid antijenlerden en az birini taşıyan grupta anlamlı olarak daha düşüktü. Remisyona girme süresi, hastalıksız yaşam süresi, total yaşam süresi, nüks oranı miyeloid antijen taşıyan ve taşımayan olgular arasında anlamlı farklılık göstermedi.

🔖

Cite This Article

USALAN, N., SURARDAMAR, A., GÜNDOĞAR, S., HATIRNAZ, N., NOYAN, F., DEMİRTUNÇ, R. (2022). Relationship between myeloid antigen expression and prognosis in the adult acute lymphoblastic leukemia. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 44 - Sayı: 4, 200–204. https://ajindex.com/articles/535674

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Preti A, Kantarjian HM. Management of Adult Acute Lymphoblastic Leukemia: Present Issues and Key Challenges. Journal of Clinical Oncology 12: 1312, 1994
  2. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD: Clinical Importance of Myeloid Antigen Expression in Adult Acute Lymphoblastic Leukemia. N Eng J Med 316:1111, 1987
  3. Boucheix C, David B., Sebban C, RacadotE., Bene MC, Bernard A, Campos L., Jouault H, Siagaux F, Lepage E., Herve P., Fiere D. Immunophenotype of Adult ALL, Clinical parameters, and Outcome: An Analysis of a Prospective Trial Including 562 Tested Patients (LALA 87). Blood 84; 1603, 1994
  4. Putti MC., Rondelli R„ Cocito MG., Arico M., Sainati L, Confer V., Guglielmi C., RajnoldiAC., Consolini R., PessionA., Zanesco L, Masera G., BiondiA., Basso G. Expression of Myelo¬id Markers Lacks Prognostic Impact in Children Treated for ALL: Italian Experience in AIEOP-ALL 88-91 Studies. Blood 92; 795, 1998
  5. Ginsberg Y.O, Huh J, Kagan J, Liang C,Stass SA. Advances in the Diagnosis of Acute Leukemia. Haematology Oncology Clinics of North America 7(1): 1993
  6. Uckun FM, SatherHN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG, Reaman GH: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 90(1): 28, 1997
  7. PuiC-H, RaimondiSC, Head DR, Schell MJ, Rivera GK, Mirro J Jr, Crist WM, Behm FG: Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 78:1327, 1991
  8. Pui Ch, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, Crist WM, Mirro J. Myeloid associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75: 198,1990
  9. Pui CH., Behm FG., Crist WM. Clinical and Biologic Relevance of Immunologic Marker Studies in Childhood Acute Lymphoblastic Leukemia. Blood 82; 343, 1993
  10. Jennnings CD, Foon KA. Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy. Blood 90; 2863, 1997.